At its October meeting, the European Commission on Drugs for HumanIty (CHMP) actively recommended the launch of ten new drugs.

At its October 2020 meeting, the European Medicines Agency's (CHMP) Committee on People's Medicines (CHMP) made a positive assessment of ten new drugs and recommended their approval for market.
picture source: RTTNews1.It is recommended to approve car-T cell therapy Tecartus from Kite, Kilead, for the treatment of patients with sleeve cell lymphoma.
2.It is recommended to approve Orchard Therapeutics' gene therapy Libmeldy for the treatment of iso-infected cerebral whiteness malnutrition (MLD).
MLD is a rare genetic disorder that affects the nervous system and leads to progressive loss of motor function and cognitive ability.
3.It is recommended to approve Allenylam's RNA interference therapy Oxlumo (lumasiran) for the treatment of primary high oxalic aciduria.
4.It is recommended that the antiretroviral drug Janssen's Rekambys (rilpivirine) and ViiV Healthcare's Vocabria (cabotegravir) be approved for hiv treatment.
5.It is recommended to approve Novrits' RNA interference therapy Leqvio (inclisiran) for the treatment of hypercholesterolemia or mixed lipid abnormalities.
6.It is recommended that Zogenix's Fenfluramine be approved for the treatment of seizures associated with Dravet syndrome.
7.It is recommended to approve Aimmune Therapeutic's Palforzia for peanut allergy in children and adolescents.
8.It is recommended that Trixeo Aerosphere be approved for adult patients with chronic obstructive pulmonary disease who have inadequate disease control.
9.It is recommended to approve Mylan's Lenalidomide (Lenalidomide), which is used to treat multiple myeloma and figilloman lymphoma.
.